Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566993 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
A Phase 3 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 3
- Development phase
- 613
- Enrollment target
NCT02566993: Completed Phase 3 study, sponsored by PharmaMar.
NCT02566993 is a Phase 3 study that has completed, run by PharmaMar. The registered enrollment target is 613 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02566993, a Phase 3 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 613 participants
- Enrollment target
Study Summary
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Primary Outcome
Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).
Interventions
- DRUG Topotecan
- DRUG Cyclophosphamide (CTX)
- DRUG Lurbinectedin (PM01183)
- DRUG Doxorubicin (DOX)
- DRUG Vincristine (VCR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2020-02-24 |
| Phase | Phase 3 |
What the finished NCT02566993 record still lists
NCT02566993 is an interventional study that assigns participants to a tested intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 5 interventions - of which Topotecan is the first listed.
NCT02566993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02566993 about?
NCT02566993 is a clinical study titled "Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer". Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
What is the current status of trial NCT02566993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 613 participants. The study started on 2016-08-30. Estimated completion is 2020-02-24.
What interventions are being tested in trial NCT02566993?
The interventions under investigation include: Topotecan (DRUG), Cyclophosphamide (CTX) (DRUG), Lurbinectedin (PM01183) (DRUG), Doxorubicin (DOX) (DRUG), Vincristine (VCR) (DRUG).
Who is sponsoring clinical trial NCT02566993?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02566993's enrollment target sits among peer trials
613 598th of 2000 higher than 1,403 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI